Achilles Therapeutics plc (ACHL)
收市後：
| 前收市價 | 0.9000 |
| 開市 | 0.9200 |
| 買盤 | 0.9084 x 100 |
| 賣出價 | 0.9717 x 100 |
| 今日波幅 | 0.9000 - 0.9703 |
| 52 週波幅 | 0.7400 - 1.7600 |
| 成交量 | |
| 平均成交量 | 652,455 |
| 市值 | 40.146M |
| Beta 值 (5 年，每月) | 1.25 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.7400 |
| 業績公佈日 | 2024年8月02日 - 2024年8月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 2.83 |
ZacksIs ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
ZacksIs Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
Here is how Acadia Healthcare (ACHC) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
InvestorPlace3 Stocks With 1,000% Upside Potential
If you’re a risk taker on the lookout for stocks with 1000% upside potential, you’d have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high. Such catalysts include promising drug candidates that are awaiting approval or going through a clinical trial. These catalysts may or may not materialize for years. If the said business disappoints by losing the drug or not getting approval, share
